Cargando…
Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy
Objective: Immune checkpoint inhibitors (ICIs) have recently demonstrated promising performance in improving the prognosis of urological cancer patients. The goal of this meta-analysis was to determine the impact of PPI use on the clinical outcomes of urological cancer patients receiving ICI therapy...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549125/ https://www.ncbi.nlm.nih.gov/pubmed/36225582 http://dx.doi.org/10.3389/fphar.2022.1018411 |
_version_ | 1784805598180671488 |
---|---|
author | Zhang, Lilong Chen, Chen Chai, Dongqi Li, Chunlei Kuang, Tianrui Liu, Li Dong, Keshuai Deng, Wenhong Wang, Weixing |
author_facet | Zhang, Lilong Chen, Chen Chai, Dongqi Li, Chunlei Kuang, Tianrui Liu, Li Dong, Keshuai Deng, Wenhong Wang, Weixing |
author_sort | Zhang, Lilong |
collection | PubMed |
description | Objective: Immune checkpoint inhibitors (ICIs) have recently demonstrated promising performance in improving the prognosis of urological cancer patients. The goal of this meta-analysis was to determine the impact of PPI use on the clinical outcomes of urological cancer patients receiving ICI therapy. Methods: Before 6 May 2022, the eligible literature was searched using PubMed, EMBASE, Cochrane Library, and Google Scholar. The clinical outcomes were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Results: A total of six articles met the inclusion criteria, and of the 1980 patients with advanced or metastatic urothelial cancers (UC) included. The meta-analysis displayed that PPI use could increase the risk of progression by 50.7% (HR: 1.507, 95% CI: 1.327–1.711, p < 0.001) and death by 58.7% (HR: 1.587, 95% CI: 1.367–1.842, p < 0.001), and reduce the ORR (OR: 0.503, 95% CI: 0.360–0.703, p < 0.001) in UC patients receiving ICIs. No significant heterogeneity and publication bias existed. Sensitivity analysis proved that the results were stable and reliable. Conclusion: The meta-analysis indicated that concomitant PPI use was significantly associated with low clinical benefit in UC patients. |
format | Online Article Text |
id | pubmed-9549125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95491252022-10-11 Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy Zhang, Lilong Chen, Chen Chai, Dongqi Li, Chunlei Kuang, Tianrui Liu, Li Dong, Keshuai Deng, Wenhong Wang, Weixing Front Pharmacol Pharmacology Objective: Immune checkpoint inhibitors (ICIs) have recently demonstrated promising performance in improving the prognosis of urological cancer patients. The goal of this meta-analysis was to determine the impact of PPI use on the clinical outcomes of urological cancer patients receiving ICI therapy. Methods: Before 6 May 2022, the eligible literature was searched using PubMed, EMBASE, Cochrane Library, and Google Scholar. The clinical outcomes were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Results: A total of six articles met the inclusion criteria, and of the 1980 patients with advanced or metastatic urothelial cancers (UC) included. The meta-analysis displayed that PPI use could increase the risk of progression by 50.7% (HR: 1.507, 95% CI: 1.327–1.711, p < 0.001) and death by 58.7% (HR: 1.587, 95% CI: 1.367–1.842, p < 0.001), and reduce the ORR (OR: 0.503, 95% CI: 0.360–0.703, p < 0.001) in UC patients receiving ICIs. No significant heterogeneity and publication bias existed. Sensitivity analysis proved that the results were stable and reliable. Conclusion: The meta-analysis indicated that concomitant PPI use was significantly associated with low clinical benefit in UC patients. Frontiers Media S.A. 2022-09-26 /pmc/articles/PMC9549125/ /pubmed/36225582 http://dx.doi.org/10.3389/fphar.2022.1018411 Text en Copyright © 2022 Zhang, Chen, Chai, Li, Kuang, Liu, Dong, Deng and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhang, Lilong Chen, Chen Chai, Dongqi Li, Chunlei Kuang, Tianrui Liu, Li Dong, Keshuai Deng, Wenhong Wang, Weixing Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy |
title | Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy |
title_full | Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy |
title_fullStr | Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy |
title_full_unstemmed | Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy |
title_short | Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy |
title_sort | effects of ppis use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549125/ https://www.ncbi.nlm.nih.gov/pubmed/36225582 http://dx.doi.org/10.3389/fphar.2022.1018411 |
work_keys_str_mv | AT zhanglilong effectsofppisuseonclinicaloutcomesofurothelialcancerpatientsreceivingimmunecheckpointinhibitortherapy AT chenchen effectsofppisuseonclinicaloutcomesofurothelialcancerpatientsreceivingimmunecheckpointinhibitortherapy AT chaidongqi effectsofppisuseonclinicaloutcomesofurothelialcancerpatientsreceivingimmunecheckpointinhibitortherapy AT lichunlei effectsofppisuseonclinicaloutcomesofurothelialcancerpatientsreceivingimmunecheckpointinhibitortherapy AT kuangtianrui effectsofppisuseonclinicaloutcomesofurothelialcancerpatientsreceivingimmunecheckpointinhibitortherapy AT liuli effectsofppisuseonclinicaloutcomesofurothelialcancerpatientsreceivingimmunecheckpointinhibitortherapy AT dongkeshuai effectsofppisuseonclinicaloutcomesofurothelialcancerpatientsreceivingimmunecheckpointinhibitortherapy AT dengwenhong effectsofppisuseonclinicaloutcomesofurothelialcancerpatientsreceivingimmunecheckpointinhibitortherapy AT wangweixing effectsofppisuseonclinicaloutcomesofurothelialcancerpatientsreceivingimmunecheckpointinhibitortherapy |